[Research Progress in the Efficacy and Safety of ALK Inhibitors 
in the Treatment of NSCLC Brain Metastasis].

Lung cancer is one of the most lethal malignancies in the world, with non-small cell lung cancer (NSCLC) accounting for approximately 80%-85% of all pathological types. Approximately 30%-55% of NSCLC patients develop brain metastases. It has been reported that 5%-6% of patients with brain metastases harbor anaplastic lymphoma kinase (ALK) fusion. ALK-positive NSCLC patients have shown significant therapeutic benefits after treatment with ALK inhibitors. Over the past decade, ALK inhibitors have rapidly evolved and now exist in three generations: first-generation drugs such as Crizotinib; second-generation drugs including Alectinib, Brigatinib, Ceritinib, and Ensartinib; and third-generation drugs like Lorlatinib. These drugs have exhibited varying efficacy in treating brain metastases in ALK-positive NSCLC patients. However, the numerous options available for ALK inhibition present a challenge for clinical decision-making. Therefore, this review aims to provide clinical guidance by summarizing the efficacy and safety of ALK inhibitors in treating NSCLC brain metastases. .【中文题目：ALK抑制剂在治疗NSCLC脑转移中的疗效及安全性研究进展】 【中文摘要：肺癌是全球死亡率最高的恶性肿瘤之一，其中非小细胞肺癌（non-small cell lung cancer, NSCLC）占所有肺癌病理类型的80%-85%。NSCLC中有30%-55%的患者发生脑转移。据估计，5%-6%的脑转移患者存在间变性淋巴瘤激酶（anaplastic lymphoma kinase, ALK）融合。ALK融合阳性NSCLC患者在接受ALK抑制剂后获得了非常显著的疗效。经过十余年的迅速发展，ALK抑制剂已经形成三代同堂的局面：即第一代——克唑替尼（Crizotinib）；第二代——阿来替尼（Alectinib）、布格替尼（Brigatinib）、塞瑞替尼（Ceritinib）、恩沙替尼（Ensartinib）；第三代——洛拉替尼（Lorlatinib）。这些药物在ALK融合阳性NSCLC脑转移患者中显示出不同的疗效。由于此类药物众多，ALK抑制剂的选择给临床医生带来了困扰。因此，本文旨在对ALK抑制剂在NSCLC脑转移中的治疗效果和安全性进行综述，以期为临床医生提供治疗选择的依据。】 【中文关键词：肺肿瘤；ALK抑制剂；脑转移；疗效；安全性】.